MedTrace Logo

Treatment of Pancreatic Cancer With Abraxane

NCT02555813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2020-10-19

No results posted yet for this study

Summary

This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine. Additionally data on dosage that is actually used in these patients will be collected. Patients who have pancreatic cancer and additional diseases can be documented in this study, too. Collected data might generate learnings on the optimal use of Abraxane in the daily routine setting.

Conditions

Interventions

DRUG

Abraxane

Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity

DRUG

Gemcitabine

Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Guenter Voraberger, MD · Celgene Austria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-08
Primary Completion
2020-09-07
Completion
2020-09-07

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02555813 on ClinicalTrials.gov